Citius Oncology, Inc.
CTORCitius Oncology is a biopharmaceutical company specializing in the development and commercialization of targeted oncology therapies.
Earnings
Next report
Date not yet announcedFinancials
Q3 2026Valuation & ratios
Competitors
By market cap
Profile
Citius Oncology is a biopharmaceutical company specializing in the development and commercialization of targeted oncology therapies. The company focuses on acquiring and advancing innovative treatments with reduced development risks, primarily through new formulations of previously approved drugs or expanded indications. Its core value proposition is centered on addressing underserved rare cancers, such as cutaneous T-cell lymphoma, using engineered protein-based therapies.
The company holds a specialized position in the rare non-Hodgkin lymphoma market with an FDA-approved therapy that features a differentiated dual mechanism of action.
FAQ
- What is Citius Oncology, Inc.'s market cap?
- Citius Oncology, Inc. (CTOR) has a market capitalization of $83.2M and trades on XNAS.
- Who are Citius Oncology, Inc.'s competitors?
- Citius Oncology, Inc.'s key competitors include Merck & Co., Citius Pharmaceuticals Inc. Common, Iovance Biotherapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Citius Oncology, Inc. partner with?
- Citius Oncology, Inc.'s notable partners include Eisai Co., Ltd., Dr. Reddy’s Laboratories, Cardinal Health, and others.
- What subsidiaries does Citius Oncology, Inc. have?
- Citius Oncology, Inc.'s subsidiaries include Citius Oncology Sub.
- Where is Citius Oncology, Inc. headquartered?
- Citius Oncology, Inc. is headquartered in United States of America. It has been publicly traded since 2024.